Ipilimumab and nivolumab (I+N) as first-line treatment of metastatic renal cell carcinoma (mRCC): A real-world review in North West of England, United Kingdom.

Jennifer Allison,Richard Griffiths,Thomas K. Waddell,Manon Pillai

Ipilimumab and nivolumab (I+N) as first-line treatment of metastatic renal cell carcinoma (mRCC): A real-world review in North West of England, United Kingdom.

2021

Jennifer Allison
Richard Griffiths
Thomas K. Waddell
Manon Pillai

295Background: Ipilimumab and Nivolumab (I+N) is now an established first line option for patients with advanced RCC of intermediate (I) or poor (P) IMDC risk score. In this retrospective review, w...

Keywords:

Oncology
Ipilimumab
Renal cell carcinoma
Internal medicine
Framingham Risk Score
Nivolumab
Medicine
north west
retrospective review
first line
first line treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations